A Phase 1/2 interventional study of pemetrexed and cisplatin in Neoplasm, Gastric, sponsored by Eli Lilly and Company. Completed at 8 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-09-28.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing cisplatin in Stomach Neoplasms — 7 open to participants now, 8 under way, 2 of them phase 3. Cisplatin · Stomach Neoplasms.
Among the 98 studies testing cisplatin in Stomach Neoplasms, this one is the 23rd largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2004, is one of 4 in phase 1/2, and was the 32nd registered.
3,406 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →7 of the 98 studies testing cisplatin in Stomach Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Krankenhaus Nordwest · Sites in Germany
Ages 18–75
City of Hope Medical Center · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18–80
Odense University Hospital · Sites in United States, Denmark, France and 2 more countries
Ages 18–80
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 67 · Phase 3 16
First in 1994; this study’s year is marked. 4 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 66 across 2,505 interventional studies indexed under Stomach Neoplasms.
Median enrollment 48 across the 90 interventional studies. Of the 76 that completed or were terminated, 27 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 98 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
17 studies in Stomach Neoplasms by Eli Lilly and Company: 3 open now, 3 under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 17 studies in Stomach Neoplasms by Eli Lilly and Company, this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2004, is the only one in phase 1/2, and was the 1st registered.
Eli Lilly and Company’s Stomach Neoplasms studies by the year they started, since 2004.
2 of the studies testing cisplatin in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06295094Odense University HospitalThe Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. | 2027-01 |
| NCT07139951Mayo ClinicHyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence | 2027-05-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 98 studies testing cisplatin in Stomach Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 17 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, single arm, open-label Phase 1/2 study of pemetrexed plus cisplatin for patients with unresectable, advanced gastric cancer who had no prior palliative chemotherapy. Phase 1 was designed to determine the optimal dose of pemetrexed for its phase 2, which has been completed and now a total of 60 qualified patients will be enrolled in the phase 2 of this study. The treating physician will determined the maximum number of cycles of pemetrexed plus cisplatin that a patient may receive in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed · Drug: cisplatin
Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression
Also known as: LY231514, Alimta
75 mg/m2, intravenous (IV), every 21 days, until disease progression
Objective Best Tumor Response
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
Time frame: baseline to measured progressive disease (Tumor assessments were performed every 2 cycles during therapy and 6-8 weeks during post-therapy until disease progression, or up to 12 months after enrollment)
Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
Time frame: time of response to progressive disease or death (Tumor assessments were performed every 2 cycles during therapy and 6-8 weeks during post-therapy until disease progression, or up to 12 months after enrollment)
Progression Free Survival
The period from study entry until disease progression or death on study, whichever occurred first.
Time frame: baseline to measured progressive disease or death (Tumor assessments were performed every 2 cycles during therapy and 6-8 weeks during post-therapy until disease progression, or up to 12 months after enrollment)
Overall Survival
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
Time frame: baseline to date of death from any cause (Survival follow-up were performed every 2 cycles during therapy and approximately every 3 months during post-therapy until death or up to 12 months after enrollment)
| Milestone | Pemetrexed + Cisplatin |
|---|---|
| Started | 69 |
| Completed | 20 |
| Not completed | 49 |
| Withdrew: Death | 33 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Physician decision | 2 |
| Withdrew: Withdrawal by subject | 8 |
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
| participants | Pemetrexed + Cisplatin |
|---|---|
| Complete Response | 1 |
| Partial Response | 15 |
| Stable Disease | 22 |
| Progressive Disease | 24 |
| Unknown | 6 |
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
| months | Pemetrexed + Cisplatin |
|---|---|
| Duration of Response | 5.4 (4.6 to 6.9) |
The period from study entry until disease progression or death on study, whichever occurred first.
| months | Pemetrexed + Cisplatin |
|---|---|
| Progression Free Survival | 4.9 (2.8 to 7.1) |
Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.
| months | Pemetrexed + Cisplatin |
|---|---|
| Overall Survival | 11.8 (7.2 to 18.5) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Cisplatin | — | — | — |
| Event | Pemetrexed + Cisplatin |
|---|---|
| IleusGastrointestinal disorders | 2/69 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 2/69 |
| NeutropeniaBlood and lymphatic system disorders | 1/69 |
| Abdominal painGastrointestinal disorders | 1/69 |
| Abdominal pain upperGastrointestinal disorders | 1/69 |
| AscitesGastrointestinal disorders | 1/69 |
| Colonic obstructionGastrointestinal disorders | 1/69 |
| VomitingGastrointestinal disorders | 1/69 |
| DehydrationMetabolism and nutrition disorders | 1/69 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/69 |
| Event | Pemetrexed + Cisplatin |
|---|---|
| NauseaGastrointestinal disorders | 37/69 |
| Haemoglobin decreasedInvestigations | 30/69 |
| FatigueGeneral disorders | 29/69 |
| AnorexiaMetabolism and nutrition disorders | 27/69 |
| VomitingGastrointestinal disorders | 26/69 |
| Neutrophil count decreasedInvestigations | 26/69 |
| ConstipationGastrointestinal disorders | 24/69 |
| NeutropeniaBlood and lymphatic system disorders | 22/69 |
| White blood cell count decreasedInvestigations | 18/69 |
| DiarrhoeaGastrointestinal disorders | 16/69 |
| Age Continuous(years) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 55.9 ± 10.20 |
| Sex: Female, Male(Participants) | Pemetrexed + Cisplatin |
|---|---|
| Female | 20 |
| Male | 49 |
| Region of Enrollment(participants) | Pemetrexed + Cisplatin |
|---|---|
| Taiwan | 22 |
| Mexico | 4 |
| Argentina | 18 |
| Korea, Republic of | 25 |
| Eastern Cooperative Oncology Group Performance Status(participants) | Pemetrexed + Cisplatin |
|---|---|
| 0 - Fully Active | 42 |
| 1 - Ambulatory, Restricted Strenuous Activity | 27 |
| Race/Ethnicity(participants) | Pemetrexed + Cisplatin |
|---|---|
| Caucasian | 1 |
| East Asian | 47 |
| Hispanic | 21 |
The record gives a start of Mar 2004, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cisplatin